Tocilizumab treatment in critical COVID-19: Report from a hospital center
Acinetobacter baumannii adult adult respiratory distress syndrome article bacterial superinfection clinical article clinical evaluation comorbidity drug therapy Horowitz index human liver toxicity male mortality nonhuman obesity Severe acute respiratory syndrome coronavirus 2 tocilizumab
; 2021(Acta Medica Peruana): Tratamiento con tocilizumab en COVID-19 crítico: Reporte de un centro hospitalario,
Article
in Spanish
| WHO COVID | ID: covidwho-1449558
ABSTRACT
A descriptive study was carried out, in which clinical and laboratory characteristics were evaluated in patients with a diagnosis of acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 infection and who received Tocilizumab. Twenty-four patients received Tocilizumab, the majority were male (95.8%), the most frequent comorbidity was obesity (33.3%). At the time of receiving Tocilizumab the median PAO2/FiO2 was 159.5 (IQR 114.5-255, 3). Twenty-one (87.5%) patients presented clinical improvement and 3 (12.5%) died. Fifteen patients (62.5%) developed hepatotoxicity, the majority grade 3 (33.3%) and three (12.5%) patients presented grade 4 liver injury. Eleven patients (45.8%) presented bacterial superinfection, the more common organism being Acinetobacter baumannii. After the administration of Tocilizumab, more than half of the patients presented an adverse reaction;despite this, mortality was low, and the majority had a clinical improvement.
Full text:
Available
Collection:
Databases of international organizations
Database:
WHO COVID
Type of study:
Experimental Studies
/
Prognostic study
Language:
Spanish
Journal:
Acinetobacter baumannii adult adult respiratory distress syndrome article bacterial superinfection clinical article clinical evaluation comorbidity drug therapy Horowitz index human liver toxicity male mortality nonhuman obesity Severe acute respiratory syndrome coronavirus 2 tocilizumab
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS